OncLive TV

John H. Strickler, MD, discusses the rationale of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Judith Karp, MD, Azra Raza, MD,, and Michelle M. Le Beau, PhD, discuss how their gender has shaped their professional lives, from working as some of the only female clinical faculty at their institutions to being compared to their male colleagues and denied opportunities when working independently from men.

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.

Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.

Christopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.

Jason Porter, MD, discusses the 3-year follow-up data from the phase 3 CheckMate-9LA trial done in patients with metastatic non–small cell lung cancer.

Neal Edward Ready, MD, PhD, discusses the practice implications of nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer.

Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Tycel Jovelle Phillips, MD, discusses the role of p53 mutations in the outcomes of patients with mantle cell lymphoma.

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.

Neha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

John H. Strickler, MD, discusses the efficacy of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Kohei Shitara, MD, discusses the rationale for the phase 3 DESTINY-Gastric04 trial in patients with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma.

Julie R. Brahmer, MD, MSc, discusses the examination of nemvaleukin alfa in solid tumors.

Adrienne G. Waks, MD, discusses the continued evaluation of immunotherapy in HER2-positive breast cancer.

Pierluigi Porcu, MD, discusses the need for diverse representation in clinical trials.

Kevin Kalinsky, MD, MS, discusses the relationship between ovarian function suppression and chemotherapy benefits in premenopausal patients with HR–positive breast cancer.

Julie R. Brahmer, MD, MSc, discusses the significance of the long-term survival data of nivolumab plus ipilimumab seen in the phase 3 CheckMate-227 trial in patients with metastatic non–small cell lung cancer.

Luis G. Paz-Ares, MD, PhD, discuses the importance of nivolumab plus ipilimumab in the treatment of patients with metastatic non–small cell lung cancer.

George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.

Edward S. Kim, MD, MBA, discusses the importance of trastuzumab deruxtecan in HER2-mutated non–small cell lung cancer.

Nir Peled, MD, PhD, FCCP, discusses the rationale of evaluating the combination of lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Heather Han, MD, discusses breakthrough data from the phase 3 DESTINY-Breast04 trial.

Amit Jain, MD, discusses the potential role of emerging biomarkers in selecting treatment with CDK7 inhibitors in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Neil Desai, MD, discusses the variety of options available for patients with localized urothelial cancer who are ineligible for cisplatin-based chemoradiation.

Howard M. Ross, MD, discusses the increase in colon and rectal cancer in young patients.

Francois-Clement Bidard, MD, PhD, discusses the importance of elacestrant in estrogen receptor–positive, HER2-negative, advanced or metastatic breast cancer.